Shots: The company has signed a supply agreement for 2 anticancer biosimilars, Herzuma (trastuzumab) and Truxima (rituximab) in Brazil. The supply of Herzuma accounts for ~80% of Brazil’s trastuzumab market […]readmore
Shots: The new data from the post-approval study evaluates the effectiveness & safety of Truxima (CT-P10) in patients with DLBCL in a real-world setting across Europe Results: @30mos. post-index, 67% […]readmore
Shots: Celltrion has presented the result of P-II study that showed that regimen of Truxima (375mg/m2) + lenalidomide (20mg, day 1-21, qd) + acalabrutinib (100mg, day 1-28, bid) (R2A) is […]readmore
Shots: In Jun 2021, the company plans for the closure of supplying Truxima to the state governments and will focus on expanding its footprints with exclusively selling it in Brazil. […]readmore
Shots: Shots: Teva and Celltrion launch Truxima (rituximab-abbs) to treat RA in combination with MTX in patients with mod.to sev. active RA who have an inadequate response to one or […]readmore
Shots: The P-III study involves assessing of Truxima vs Rituxan in 140 patients with AFL for 40mos. across India, Japan, Russia, and the EU, including Germany and Spain The P-III […]readmore
Shots: Teva and Celltrion launch Truxima (rituximab-abbs) injection as the first biosimilar referencing Roche’s Rituxan (rituximab) to be available in the US by the week of November 11, addressing the […]readmore
Shots: The approval is based on non-inferiority data demonstrating biosimilarity in pharmacology, immunogenicity, clinical efficacy with safety, potency and purity when compared to reference medicine (rituxan) Truxima is a mAb, […]readmore
Copyright © 2020 Digiqole. All Right Reserved.